{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"65","upperLimit":"93","value":"82"},{"groupId":"OG001","lowerLimit":"53","upperLimit":"85","value":"71"}]}],"title":"CR + VGPR + PR"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"20","upperLimit":"55","value":"36"},{"groupId":"OG001","lowerLimit":"17","upperLimit":"51","value":"32"}]}],"title":"CR + VGPR"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5","upperLimit":"32","value":"15"},{"groupId":"OG001","lowerLimit":"3","upperLimit":"27","value":"12"}]}],"title":"CR"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"9","upperLimit":"39","value":"21"},{"groupId":"OG001","lowerLimit":"9","upperLimit":"38","value":"21"}]}],"title":"VGPR"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"48","upperLimit":"82","value":"67"},{"groupId":"OG001","lowerLimit":"41","upperLimit":"75","value":"59"}]}],"title":"PR"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"7","upperLimit":"35","value":"18"},{"groupId":"OG001","lowerLimit":"7","upperLimit":"35","value":"18"}]}],"title":"SD"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"0","value":"0"},{"groupId":"OG001","lowerLimit":"1","upperLimit":"20","value":"6"}]}],"title":"PD"}],"denoms":[{"counts":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"34"}],"units":"Participants"}],"description":"Percentage of participants with CR + VGPR + PR (ORR), CR, VGPR, PR, SD, PD according to IMWG criteria. CR=negative immunofixation of serum and urine; disappearance of soft tissue plasmacytomas;\\<5% PC in bone marrow. VGPR=serum and urine M-component detectable by immunofixation but not on electrophoresis or 90% reduction in serum M-component plus urine M-component \\<100 mg/24 hour. PR=50% reduction of serum M-protein and reduction in 24 hour urine M-protein by 90% or \\<200 mg/24 hour or decrease 50% difference between involved FLC levels or 50% reduction in bone marrow plasma cells if baseline percentage was 30%; and if present at Baseline, 50% reduction in the size of soft tissue plasmacytomas. SD=not meeting criteria for VGPR, PR or PD. PD=25% increase in lowest value any of the following: serum M-component, urine M-component, difference between involved and uninvolved FLC levels, bone marrow PC percentage; new or increase in size of existing bone lesions or soft tissue plasmacytomas.","dispersionType":"95% Confidence Interval","groups":[{"description":"Ixazomib 4.0 mg, capsules, orally, on Days 1, 8, 15 of a 28-day cycle until progressive disease (PD)/death or unacceptable toxicity \\[13 cycles in the Induction Phase continuing in the Maintenance Phase for up to 36 Months\\] and cyclophosphamide (CYC) 300 mg/m\\^2, tablets, orally, on Days 1, 8 and 15 of a 28-day cycle for 13 cycles or until PD/death or unacceptable toxicity and dexamethasone (DEX) 40 mg, tablets, orally, on Days 1, 8, 15 and 22 (dose reduced to 20 mg for patients \\>75 years) of a 28-day cycle for 13 cycles or until PD/death or unacceptable toxicity in participants with NDMM.","id":"OG000","title":"Ixazomib 4.0 mg + CYC 300 mg/m^2 + DEX 40 mg (NDMM)"},{"description":"Ixazomib 4.0 mg, capsules, orally, on Days 1, 8, 15 of a 28-day cycle until PD/death or unacceptable toxicity \\[13 cycles in the Induction Phase continuing in the Maintenance Phase for up to 36 Months\\] and cyclophosphamide (CYC) 400 mg/m\\^2, tablets, orally, on Days 1, 8 and 15 of a 28-day cycle for 13 cycles or until PD/death or unacceptable toxicity and dexamethasone (DEX) 40 mg, tablets, orally, on Days 1, 8, 15 and 22 (dose reduced to 20 mg for patients \\>75 years) of a 28-day cycle for 13 cycles or until PD/death or unacceptable toxicity in participants with NDMM.","id":"OG001","title":"Ixazomib 4.0 mg + CYC 400 mg/m^2 + DEX 40 mg (NDMM)"}],"paramType":"NUMBER","populationDescription":"Response Evaluable Population was defined as participants who received at least 2 of the 3 ixazomib doses during Cycle 1, had measurable disease at Baseline, and at least 1 postbaseline response assessment.","reportingStatus":"POSTED","timeFrame":"Day 1 of each 28-day Cycle (Up to 45 months)","title":"Percentage of Participants With CR + VGPR + PR (ORR), CR + VGPR, CR, VGPR, PR, SD and PD Throughout the Entire Treatment Period in NDMM Participants","type":"SECONDARY","unitOfMeasure":"percentage of participants"}